Point your AI agent at freehire and let it find you a job.

Get the CLI →

Karius

Genomic blood tests for rapid identification of infectious pathogens.

H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.
Discussion
biotechhealth-techhealthcaremedical-devices

Company facts

Founded
2014
Employees
180
Headquarters
United States
CEO
Alec Ford
Type
Private
Funding
Series C · $100M · 2024

About

Karius, Inc. operates with the vision of creating a world where infectious diseases are no longer a major threat to human health. By leveraging advanced technologies, Karius focuses on enhancing diagnostic insights crucial for effective treatment. The company's flagship product, the Karius Spectrum®, utilizes cutting-edge clinical metagenomics to perform rapid, non-invasive detection of more than 1,000 pathogens from a single blood sample. This innovative testing method aids healthcare providers in diagnosing life-threatening infections more quickly than traditional methods. The Karius Spectrum test works by identifying microbial cell-free DNA (mcfDNA) circulating in the bloodstream. This approach allows for the rapid diagnosis of infections that are often difficult to identify through conventional diagnostic tests. By streamlining the testing process, Karius enhances the speed with which clinicians can make informed treatment decisions, ultimately leading to better patient outcomes. Additionally, Karius is committed to continuous improvement and staying at the forefront of technological advancements in genomics and artificial intelligence.

5 jobs

Tailor your CV for this role?

We couldn't check your fit for this role — add a CV to your profile to see it next time.

A new version of freehire is available